Saturday, July 11, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “therapy”

782 pharma patents match "therapy" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 782
Index total 30,257
Page 8 / 33

Quick answer

This filtered view shows 782 pharmaceutical patents matching "therapy" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

782 results for “therapy” · 30,257 patents in full index Clear search

  1. US 11566076

    Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected cancers

    Five Prime Therapeutics, Inc. · Granted Jan 31, 2023 · Expires Jan 26, 2043

    granted

  2. US 11559583

    Anti-CSF1R antibody and agonistic anti-CD40 antibody combination therapy for cancer

    Five Prime Therapeutics, Inc. · Granted Jan 24, 2023 · Expires Jan 19, 2043

    granted

  3. US 11541077

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Jan 3, 2023 · Expires Dec 29, 2042

    granted

  4. US 11534453

    RNAi therapy for hepatitis B virus infection

    Arrowhead Pharmaceuticals, Inc. · Granted Dec 27, 2022 · Expires Dec 22, 2042

    granted

  5. US 11529372

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Dec 20, 2022 · Expires Dec 15, 2042

    granted

  6. US 11519007

    Tumor-navigating, self-eradicating, trail-armed salmonella for precision cancer therapy

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Dec 6, 2022 · Expires Dec 1, 2042

    granted

  7. US 11517592

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Dec 6, 2022 · Expires Dec 1, 2042

    granted

  8. US 11510998

    Gene therapy for combined methylmalonic acidemia/aciduria and hyperhomocysteinemia/homocystinuria, cobalamin C type, and deficiency of MMACHC

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Nov 29, 2022 · Expires Nov 24, 2042

    granted

  9. US 11510929

    Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids

    The Regents of the University of California · Granted Nov 29, 2022 · Expires Nov 24, 2042

    granted

  10. US 11505782

    Cell-based vehicles for potentiation of viral therapy

    Calidi Biotherapeutics, Inc. · Granted Nov 22, 2022 · Expires Nov 17, 2042

    granted

  11. US 11504427

    Acoustic and ultrasound-based mechanogenetics and thermogenetics for immunotherapy

    The Regents of the University of California · Granted Nov 22, 2022 · Expires Nov 17, 2042

    granted

  12. US 11504426

    Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 22, 2022 · Expires Nov 17, 2042

    granted

  13. US 11497781

    Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor

    CG ONCOLOGY, INC. · Granted Nov 15, 2022 · Expires Nov 10, 2042

    granted

  14. US 11497770

    Compositions and methods for treating cancer with TSLPR-CD19 or TSLPR-CD22 immunotherapy

    The Regents of the University of Colorado · Granted Nov 15, 2022 · Expires Nov 10, 2042

    granted

  15. US 11497713

    Combination taxoid nanoemulsion with immunotherapy in cancer

    Northwestern University · Granted Nov 15, 2022 · Expires Nov 10, 2042

    granted

  16. US 11497740

    Use of Jumonji C demethylase inhibitors for the treatment and prevention of chemotherapy resistance and radioresistance in cancer

    The Board of Regents of the University of Texas System · Granted Nov 15, 2022 · Expires Nov 10, 2042

    granted

  17. US 11492388

    Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A

    Takeda Pharmaceutical Company Limited · Granted Nov 8, 2022 · Expires Nov 3, 2042

    granted

  18. US 11491187

    Methods of conditioning patients for T cell therapy

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Nov 8, 2022 · Expires Nov 3, 2042

    granted

  19. US 11485788

    Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R inhibitor

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 1, 2022 · Expires Oct 27, 2042

    granted

  20. US 11478511

    Lymphocyte biomarkers for determining the clinical response to cell therapy

    Takeda Pharmaceutical Company Limited · Granted Oct 25, 2022 · Expires Oct 20, 2042

    granted

  21. US 11464801

    Compositions and methods for treating cancer with anti-CD33 immunotherapy

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Oct 11, 2022 · Expires Oct 6, 2042

    granted

  22. US 11464856

    Combination therapy using inhibitors of human growth and differentiation factor 15 (GDF-15) and immune checkpoint blockers

    Julius-Maximilians-Universitat Wurzburg · Granted Oct 11, 2022 · Expires Oct 6, 2042

    granted

  23. US 11458127

    Methods of treating brain tumors using combination therapy

    Agios Pharmaceuticals, Inc. · Granted Oct 4, 2022 · Expires Sep 29, 2042

    granted

  24. US 11458171

    Engineering stem cells for cancer therapy

    China Medical University · Granted Oct 4, 2022 · Expires Sep 29, 2042

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.